ATE518520T1 - Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen - Google Patents

Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen

Info

Publication number: ATE518520T1
Authority: AT; Austria
Prior art keywords: mometasone furoate; lung diseases; treat airway; allergic; airway
Prior art date: 1994-01-27

Application number

AT01119613T

Other languages

English (en)

Inventor

Joel A Sequeira

Keith B Nolop

Nagamani Nagabhushan

Francis M Cuss

Imtiaz A Chaudry

James E Patrick

Mitchell Cayen

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-27

Filing date

1995-01-26

Publication date

2011-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE518520(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-01-26 Application filed by Schering Corp filed Critical Schering Corp

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE518520T1 publication Critical patent/ATE518520T1/de

Links

229960002744 mometasone furoate Drugs 0.000 title abstract 2
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 title abstract 2
208000019693 Lung disease Diseases 0.000 title 1
208000023504 respiratory system disease Diseases 0.000 title 1
230000000172 allergic effect Effects 0.000 abstract 2
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
210000004072 lung Anatomy 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
229940071648 metered dose inhaler Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000037916 non-allergic rhinitis Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01119613T 1994-01-27 1995-01-26 Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen ATE518520T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18837294A	1994-01-27	1994-01-27

Publications (1)

Publication Number	Publication Date
ATE518520T1 true ATE518520T1 (de)	2011-08-15

Family

ID=22692858

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
AT95909242T ATE216243T1 (de)	1994-01-27	1995-01-26	Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen
AT02001144T ATE531364T1 (de)	1994-01-27	1995-01-26	Verwendung von mometason-furoat in einer adjuvans-therapie
AT09007995T ATE519489T1 (de)	1994-01-27	1995-01-26	Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen
AT01119613T ATE518520T1 (de)	1994-01-27	1995-01-26	Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen
AT01119614T ATE525075T1 (de)	1994-01-27	1995-01-26	Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
AT95909242T ATE216243T1 (de)	1994-01-27	1995-01-26	Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen
AT02001144T ATE531364T1 (de)	1994-01-27	1995-01-26	Verwendung von mometason-furoat in einer adjuvans-therapie
AT09007995T ATE519489T1 (de)	1994-01-27	1995-01-26	Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT01119614T ATE525075T1 (de)	1994-01-27	1995-01-26	Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen

Country Status (29)

Country	Link
EP (6)	EP1174139B1 (de)
JP (6)	JP3480736B2 (de)
KR (1)	KR100234864B1 (de)
CN (4)	CN101164542A (de)
AT (5)	ATE216243T1 (de)
AU (1)	AU691880B2 (de)
CA (1)	CA2182086C (de)
CO (1)	CO4340692A1 (de)
CY (2)	CY2616B2 (de)
CZ (1)	CZ219196A3 (de)
DE (1)	DE69526425T2 (de)
DK (3)	DK2156840T3 (de)
ES (3)	ES2173947T3 (de)
FI (2)	FI122395B (de)
HK (4)	HK1040911B (de)
HU (1)	HU227837B1 (de)
IL (1)	IL112459A (de)
MX (1)	MX9602246A (de)
MY (1)	MY114665A (de)
NO (2)	NO314535B1 (de)
NZ (1)	NZ279979A (de)
PE (1)	PE44995A1 (de)
PL (1)	PL315575A1 (de)
PT (3)	PT2156840E (de)
SG (1)	SG47387A1 (de)
SK (1)	SK283338B6 (de)
TW (1)	TW329387B (de)
WO (1)	WO1995020393A1 (de)
ZA (1)	ZA95637B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE44995A1 (es) *	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
DE69731473T2 (de)	1996-05-09	2005-10-27	Amrad Operations Pty. Ltd., Richmond	Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
US6068832A (en) *	1996-08-29	2000-05-30	Schering Corporation	Chlorofluorocarbon-free mometasone furoate aerosol formulations
CN1162157C (zh) *	1996-08-29	2004-08-18	先灵公司	无氯氟烃的糠酸莫米他松气溶胶制剂
US5968547A (en)	1997-02-24	1999-10-19	Euro-Celtique, S.A.	Method of providing sustained analgesia with buprenorphine
US6503537B2 (en)	1997-03-20	2003-01-07	Schering Corporation	Preparation of powder agglomerates
US6495167B2 (en)	1997-03-20	2002-12-17	Schering Corporation	Preparation of powder agglomerates
CZ295460B6 (cs) *	1997-03-20	2005-08-17	Schering Corporation	Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující
ES2172217T3 (es) *	1997-10-09	2002-09-16	Schering Corp	Suspensiones de furoato de mometasona para nebulizacion.
MY133181A (en) *	1998-09-10	2007-10-31	Schering Corp	Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en)	1999-03-03	1999-04-28	Novartis Ag	Organic compounds
SE9900833D0 (sv) *	1999-03-09	1999-03-09	Astra Ab	Novel combination
EP1227812B1 (de) *	1999-10-08	2007-04-18	Schering Corporation	Topische nasenbehandlung mit desloratadin und mometason furoat
AR029189A1 (es) *	1999-11-02	2003-06-18	Smithkline Beecham Corp	Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
GB0015876D0 (en)	2000-06-28	2000-08-23	Novartis Ag	Organic compounds
CA2417973A1 (en) *	2000-08-04	2002-02-14	Longwood Pharmaceutical Research, Inc.	Formulations of mometasone and a bronchodilator for pulmonary administration
ATE396733T1 (de)	2000-12-22	2008-06-15	Nippon Shinyaku Co Ltd	Prophylaktische/therapeutische mittel für entzündliche atemwegserkrankungen
GB0207906D0 (en)	2002-04-05	2002-05-15	3M Innovative Properties Co	Formoterol and mometasone aerosol formulations
JP2007506768A (ja) *	2003-09-26	2007-03-22	シェーリング　コーポレイション	肺疾患処置
EP1680084A2 (de) *	2003-10-21	2006-07-19	Direct-Haler A/S	Mehrrouten-medikament zur behandlung von rhinitis und asthma
WO2005044187A2 (en) *	2003-10-28	2005-05-19	Glaxo Group Limited	Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
PT1711164E (pt) *	2004-01-21	2010-06-28	Schering Corp	Método de tratamento da rinossinusite aguda
JP4893999B2 (ja) *	2004-10-22	2012-03-07	小野薬品工業株式会社	吸入用医薬組成物
US8679545B2 (en)	2005-11-12	2014-03-25	The Regents Of The University Of California	Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en)	2005-11-12	2012-12-04	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en)	2005-11-12	2013-07-30	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090131386A1 (en)	2007-11-13	2009-05-21	Meritage Pharma, Inc.	Compositions for the treatment of inflammation of the gastrointestinal tract
DK3354276T3 (da)	2007-11-13	2020-03-30	Meritage Pharma Inc	Sammensætninger til behandlingen af gastrointestinal inflammation
EP2309858A4 (de)	2008-07-31	2011-09-14	Dekel Pharmaceuticals Ltd	Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
CA2734763C (en) *	2008-08-20	2016-06-28	Ranjan Dohil	Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2012505236A (ja) *	2008-10-10	2012-03-01	シェーリングコーポレイション	コルチコステロイド組成物およびそれの治療方法
US9937189B2 (en)	2013-09-13	2018-04-10	Glenmark Specialty S.A.	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en)	2013-09-13	2016-06-21	Glenmark Specialty S.A.	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10016443B2 (en)	2013-10-04	2018-07-10	Glenmark Specialty S.A.	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
UA120587C2 (uk)	2013-10-04	2020-01-10	Гленмарк Спешіалті С.А.	Спосіб лікування алергічного риніту з використанням комбінації мометазону та олопатадину
US10548907B2 (en)	2013-10-04	2020-02-04	Glenmark Specialty S.A.	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en)	2013-10-04	2020-05-19	Glenmark Specialty S.A.	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en)	2013-10-04	2020-09-01	Glenmark Specialty S.A.	Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en)	2014-10-03	2023-06-20	Glenmark Specialty S.A.	Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107260665B (zh) *	2016-04-08	2021-03-30	天津金耀集团有限公司	一种吸入用糠酸莫米松混悬液组合物
EP3755375B1 (de)	2018-02-23	2025-03-05	Glenmark Specialty S.A.	Behandlung von allergischer rhinitis bei pädiatrischen patienten unter verwendung einer kombination von mometason und olopatadin
US12303635B2 (en)	2018-04-16	2025-05-20	Glenmark Specialty S.A.	Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN113933415B (zh) *	2021-09-30	2023-03-24	北京阳光德美医药科技有限公司	一种hplc-ms/ms测定人血浆中糠酸酯浓度的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE8790T1 (de)	1981-02-02	1984-08-15	Schering Corporation	Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
KR890000664B1 (ko) *	1981-10-19	1989-03-22	바리 안소니 뉴우샘	미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4731447A (en)	1985-05-13	1988-03-15	Schering Corporation	Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4972830A (en)	1985-07-31	1990-11-27	Vortran Medical Technology, Inc.	Inhalation device and method
US4873335A (en)	1986-03-12	1989-10-10	Schering Corporation	3-phenethyl-2-benzene-amides or aza-derivatives thereof
US4910192A (en) *	1987-12-04	1990-03-20	Sri International	Topically active steroidal anti-inflammatory agents
DE69034007T2 (de) *	1989-04-28	2003-05-08	Riker Laboratories Inc., Northridge	Inhalationsvorrichtung für Trockenpulver
ES2071306T3 (es) *	1990-03-23	1995-06-16	Minnesota Mining & Mfg	El uso de tensioactivos fluorados solubles para la preparacion de formulaciones aerosoles dosificadas.
CA2091360C (en) *	1990-09-10	1997-04-08	Pui-Ho Yuen	Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
EP0512090B2 (de) *	1990-10-16	2006-11-22	Sonoran Desert Chemicals LLC	Behandlung von entzündungen
JP2769925B2 (ja) *	1990-10-18	1998-06-25	ミネソタマイニングアンドマニュファクチャリングカンパニー	ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
GB9105705D0 (en) *	1991-03-18	1991-05-01	Sandoz Ltd	Improvements in or relating to organic compounds
US5474759A (en) *	1991-06-10	1995-12-12	Schering Corporation	Non-chlorofluorocarbon aerosol formulations
ES2180592T3 (es)	1991-06-10	2003-02-16	Schering Corp	Formulaciones en aerosol libres de clorofluorocarbonos.
ATE137675T1 (de)	1991-06-26	1996-05-15	Schering Corp	Inhalator für medikamente in pulverform
DE4140689B4 (de) *	1991-12-10	2007-11-22	Boehringer Ingelheim Kg	Inhalationspulver und Verfahren zu ihrer Herstellung
DE69205177T2 (de) *	1991-12-12	1996-03-21	Glaxo Group Ltd., Greenford, Middlesex	Pharmazeutische Aerosolformulierung.
IL104068A (en) *	1991-12-12	1998-10-30	Glaxo Group Ltd	Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DE69227257T2 (de) *	1991-12-12	1999-03-25	Glaxo Group Ltd	Arzneimittel
US5607662A (en) *	1992-03-10	1997-03-04	Fisons, Plc	Pharmaceutical inhalation compositions
GB9207400D0 (en) *	1992-04-02	1992-05-13	Smithkline Beecham Plc	Novel use
PE44995A1 (es) *	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

1995
- 1995-01-24 PE PE1995260142A patent/PE44995A1/es not_active Application Discontinuation
- 1995-01-26 SK SK822-96A patent/SK283338B6/sk not_active IP Right Cessation
- 1995-01-26 DK DK09007995.5T patent/DK2156840T3/da active
- 1995-01-26 DE DE69526425T patent/DE69526425T2/de not_active Expired - Lifetime
- 1995-01-26 TW TW084100705A patent/TW329387B/zh not_active IP Right Cessation
- 1995-01-26 IL IL11245995A patent/IL112459A/xx not_active IP Right Cessation
- 1995-01-26 DK DK01119613.6T patent/DK1174138T3/da active
- 1995-01-26 EP EP01119614A patent/EP1174139B1/de not_active Expired - Lifetime
- 1995-01-26 EP EP02001144A patent/EP1201242B1/de not_active Expired - Lifetime
- 1995-01-26 AT AT95909242T patent/ATE216243T1/de active
- 1995-01-26 ES ES95909242T patent/ES2173947T3/es not_active Expired - Lifetime
- 1995-01-26 MX MX9602246A patent/MX9602246A/es active IP Right Grant
- 1995-01-26 CZ CZ962191A patent/CZ219196A3/cs unknown
- 1995-01-26 NZ NZ279979A patent/NZ279979A/en not_active IP Right Cessation
- 1995-01-26 PT PT09007995T patent/PT2156840E/pt unknown
- 1995-01-26 EP EP01119613A patent/EP1174138B1/de not_active Expired - Lifetime
- 1995-01-26 EP EP01119615A patent/EP1192946A1/de not_active Ceased
- 1995-01-26 ES ES01119613T patent/ES2368827T3/es not_active Expired - Lifetime
- 1995-01-26 PT PT95909242T patent/PT740550E/pt unknown
- 1995-01-26 ES ES09007995T patent/ES2369516T3/es not_active Expired - Lifetime
- 1995-01-26 AT AT02001144T patent/ATE531364T1/de active
- 1995-01-26 PL PL95315575A patent/PL315575A1/xx unknown
- 1995-01-26 KR KR1019960704076A patent/KR100234864B1/ko not_active Expired - Lifetime
- 1995-01-26 CN CNA2007101867146A patent/CN101164542A/zh active Pending
- 1995-01-26 SG SG1996000423A patent/SG47387A1/en unknown
- 1995-01-26 ZA ZA95637A patent/ZA95637B/xx unknown
- 1995-01-26 CO CO95002738A patent/CO4340692A1/es unknown
- 1995-01-26 AT AT09007995T patent/ATE519489T1/de active
- 1995-01-26 DK DK95909242T patent/DK0740550T3/da active
- 1995-01-26 WO PCT/US1995/000550 patent/WO1995020393A1/en not_active Ceased
- 1995-01-26 EP EP09007995A patent/EP2156840B1/de not_active Expired - Lifetime
- 1995-01-26 PT PT01119613T patent/PT1174138E/pt unknown
- 1995-01-26 AT AT01119613T patent/ATE518520T1/de active
- 1995-01-26 CN CNB2004100324736A patent/CN100441192C/zh not_active Expired - Lifetime
- 1995-01-26 HU HU9602043A patent/HU227837B1/hu unknown
- 1995-01-26 CN CNB951913603A patent/CN100358528C/zh not_active Expired - Lifetime
- 1995-01-26 CN CNA2007101867131A patent/CN101156860A/zh active Pending
- 1995-01-26 JP JP52007495A patent/JP3480736B2/ja not_active Expired - Lifetime
- 1995-01-26 EP EP95909242A patent/EP0740550B1/de not_active Expired - Lifetime
- 1995-01-26 AU AU17271/95A patent/AU691880B2/en not_active Expired
- 1995-01-26 CA CA002182086A patent/CA2182086C/en not_active Expired - Lifetime
- 1995-01-26 AT AT01119614T patent/ATE525075T1/de not_active IP Right Cessation
- 1995-01-27 MY MYPI95000213A patent/MY114665A/en unknown
1996
- 1996-07-12 FI FI962828A patent/FI122395B/fi not_active IP Right Cessation
- 1996-07-26 NO NO19963132A patent/NO314535B1/no not_active IP Right Cessation
1998
- 1998-11-30 JP JP10340817A patent/JPH11286447A/ja not_active Withdrawn
2002
- 2002-02-27 HK HK02101490.1A patent/HK1040911B/en not_active IP Right Cessation
- 2002-02-27 HK HK02101491.0A patent/HK1040912A1/en unknown
- 2002-04-08 HK HK02102575.7A patent/HK1040918A1/en unknown
- 2002-05-21 HK HK02103767.3A patent/HK1041829A1/en unknown
- 2002-10-17 NO NO20025002A patent/NO328698B1/no not_active IP Right Cessation
2003
- 2003-06-03 JP JP2003158657A patent/JP2003313128A/ja not_active Withdrawn
2007
- 2007-10-19 JP JP2007273211A patent/JP2008031184A/ja not_active Withdrawn
2008
- 2008-07-02 JP JP2008174020A patent/JP5247265B2/ja not_active Expired - Lifetime
2011
- 2011-07-08 FI FI20115742A patent/FI123580B/fi not_active IP Right Cessation
- 2011-10-27 CY CY1100006A patent/CY2616B2/xx unknown
- 2011-10-27 CY CY1100007A patent/CY2617B2/xx unknown
- 2011-11-09 JP JP2011245814A patent/JP2012036222A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
IL112459A0 (en)	1995-03-30
NO963132D0 (no)	1996-07-26
FI20115742L (fi)	2011-07-08
EP2156840A2 (de)	2010-02-24
EP0740550A1 (de)	1996-11-06
ATE216243T1 (de)	2002-05-15
EP1201242A2 (de)	2002-05-02
CY2616B2 (en)	2012-05-23
PT1174138E (pt)	2011-10-03
EP1201242A3 (de)	2003-12-03
AU691880B2 (en)	1998-05-28
MY114665A (en)	2002-12-31
PT2156840E (pt)	2011-10-18
CN1531967A (zh)	2004-09-29
DE69526425D1 (de)	2002-05-23
DE69526425T2 (de)	2002-12-05
EP1174139A2 (de)	2002-01-23
FI962828L (fi)	1996-07-12
SK283338B6 (sk)	2003-06-03
PL315575A1 (en)	1996-11-12
DK2156840T3 (da)	2011-11-21
ATE525075T1 (de)	2011-10-15
EP1192946A1 (de)	2002-04-03
HK1135331A1 (en)	2010-06-04
WO1995020393A1 (en)	1995-08-03
HK1040911B (en)	2011-11-18
DK1174138T3 (da)	2011-11-21
FI962828A0 (fi)	1996-07-12
SK82296A3 (en)	1997-03-05
HK1040918A1 (en)	2002-06-28
CO4340692A1 (es)	1996-07-30
EP2156840A3 (de)	2010-05-19
HU227837B1 (en)	2012-05-02
IL112459A (en)	1999-04-11
AU1727195A (en)	1995-08-15
CN100358528C (zh)	2008-01-02
CA2182086C (en)	2000-04-11
EP2156840B1 (de)	2011-08-10
PE44995A1 (es)	1995-12-18
ATE519489T1 (de)	2011-08-15
EP1174139B1 (de)	2011-09-21
CZ219196A3 (en)	1996-12-11
JPH11286447A (ja)	1999-10-19
JPH09501700A (ja)	1997-02-18
TW329387B (en)	1998-04-11
DK0740550T3 (da)	2002-06-24
CN101156860A (zh)	2008-04-09
FI123580B (fi)	2013-07-31
CA2182086A1 (en)	1995-08-03
HU9602043D0 (en)	1996-09-30
JP2008031184A (ja)	2008-02-14
EP1201242B1 (de)	2011-11-02
ES2173947T3 (es)	2002-11-01
JP3480736B2 (ja)	2003-12-22
NO963132L (no)	1996-09-26
HK1041829A1 (en)	2002-07-26
CN1139384A (zh)	1997-01-01
HK1040912A1 (en)	2002-06-28
FI122395B (fi)	2011-12-30
EP1174139A3 (de)	2002-01-30
PT740550E (pt)	2002-08-30
KR100234864B1 (ko)	1999-12-15
NO20025002L (no)	1996-09-26
JP2003313128A (ja)	2003-11-06
HUT74884A (en)	1997-02-28
JP2008285497A (ja)	2008-11-27
MX9602246A (es)	1997-07-31
HK1040911A1 (en)	2002-06-28
CN101164542A (zh)	2008-04-23
ATE531364T1 (de)	2011-11-15
ZA95637B (en)	1995-07-26
NO20025002D0 (no)	2002-10-17
ES2369516T3 (es)	2011-12-01
EP1174138B1 (de)	2011-08-03
EP0740550B1 (de)	2002-04-17
JP2012036222A (ja)	2012-02-23
NO328698B1 (no)	2010-04-26
JP5247265B2 (ja)	2013-07-24
ES2368827T3 (es)	2011-11-22
EP1174138A3 (de)	2002-01-30
CY2617B2 (en)	2012-05-23
SG47387A1 (en)	1998-04-17
CN100441192C (zh)	2008-12-10
NO314535B1 (no)	2003-04-07
NZ279979A (en)	2001-03-30
EP1174138A2 (de)	2002-01-23

Legal Events

Date

Code

Title

Description

2012-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1174138

Country of ref document: EP

Publication	Publication Date	Title
ATE216243T1 (de)	2002-05-15	Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen
CY1109030T1 (el)	2014-07-02	Συνθεση για εισπνοη
ATE205389T1 (de)	2001-09-15	Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
DE69731473D1 (de)	2004-12-09	Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
DE60002885D1 (de)	2003-06-26	Wässrige formulierung zur nasalen verabreichung
ATE33099T1 (de)	1988-04-15	Verwendung von l-fukose zur herstellung einer inhalationszusammensetzung und verfahren zur herstellung von l-fukose.